[Featured Stock] Short Selling War Ignites Domestically?… Celltrion Up 9%

[Asia Economy Reporter Ji Yeon-jin] On the 1st, Celltrion's stock price is soaring. The news that its main product, the biosimilar Remsima SC, received sales approval in Canada, along with the global short-selling war triggered by the U.S. gaming company 'GameStop,' is believed to have influenced this rise.

At 9:22 a.m. on the same day, Celltrion was trading at 354,000 won, up 9.45% compared to the previous session. Celltrion announced on the 1st that Remsima SC, the world's first subcutaneous injection formulation of infliximab for autoimmune disease treatment, obtained sales approval from Health Canada on the 28th (local time).

Some analysts suggest that related to the U.S. GameStop short-selling issue, domestic individual investors are reflecting a 'anti-short-selling movement' in the stock price by joining the effort against Celltrion, which currently has the highest short-selling balance.

This content was produced with the assistance of AI translation services.